NeuroMetrix (NASDAQ:NURO) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research note issued to investors on Tuesday morning. The firm issued a sell rating on the medical device company’s stock.

NeuroMetrix Stock Performance

Shares of NASDAQ:NURO opened at $4.04 on Tuesday. NeuroMetrix has a one year low of $2.66 and a one year high of $4.73. The firm has a market cap of $8.25 million, a PE ratio of -0.88 and a beta of 2.20. The firm’s 50 day simple moving average is $3.98 and its 200-day simple moving average is $3.86.

NeuroMetrix (NASDAQ:NURO) last posted its earnings results on Tuesday, November 5th. The medical device company reported ($0.75) EPS for the quarter. The firm had revenue of $0.59 million for the quarter. NeuroMetrix had a negative net margin of 203.71% and a negative return on equity of 42.56%. During the same period last year, the firm earned ($1.66) earnings per share.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.